WaubantEBanwellBWassmerE, et al. Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG. Neurology2019; 92(22): E2538–E2549.
3.
KnopfHWolfIKSarganasG, et al. Off-label medicine use in children and adolescents: Results of a population-based study in Germany. BMC Public Health2013; 13(1): 1.
4.
Bar-OrAHintzenRQDaleRC, et al. Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. Neurology2016; 87(9Suppl. 2): S12–S19.
5.
RenouxCVukusicSMikaeloffY, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med2007; 356(25): 2603–2613.
6.
AmatoMPKruppLBCharvetLE, et al. Pediatric multiple sclerosis: Cognition and mood. Neurology2016; 87(9): S82–S87.
7.
GormanMPHealyBCPolgar-TurcsanyiM, et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol2009; 66(1): 54–59.
8.
WaubantEChabasDOkudaDT, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol2009; 66(8): 967–971.
9.
ChitnisTArnoldDLBanwellB, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med2018; 379(11): 1017–1027.
10.
VerheyLHSignoriAArnoldDL, et al. Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. Neurology2013; 81(14): 1215–1221.
